Genexine is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics. Our goal is to bring to patients medicines that will transform their lives.


Young Chul Sung
Chief Technology Officer
Kyu Don Kim
You Suk Suh
Jong Sup Park
M.D., Ph.D.
Gynecologic Oncologist
Executive Vice President,
Chief Medical Officer
Hyi-Jeong Ji
Executive Vice President,
Head of Bio Research Institute
Kwang Ho Kim
Executive Vice President,
Chief Operating Officer
Young-Joon Lee
Executive Vice President,
Chief Strategy Officer(CSO)
Jung Won Woo
Senior Vice President,
Head of Clinical Division
Yong Min Won
Senior Vice President, CFO
   Previous Next   
  • Young Chul Sung, Ph.D.
    Chairman, Chief Technology Officer
    Young Chul Sung is the founder and former CEO of Genexine. He currently serves as Chief Technology Officer of Genexine. He is also a professor at POSTECH Department of Life Sciences and founder of POSTECH- Catholic Bio Medical Institute. Dr. Sung is an expert immunologist and has published over one hundred scientific articles. He has served on editorial boards of many biological organizations and has earned numerous awards including the most recently the Scientists of the Year 2014 from Korea Science Journalist Association. Dr. Sung received his B.S. from Yonsei University, Ph.D degree from University of Minnesota and postdoctoral training at Harvard University.
  • Kyu Don Kim, Ph.D. MBA
    Kyu Don Kim joined Genexine in December 2015 as Excutive Vice President and he is in charge of Business. Prior to joining Genexine, Dr Kim was CEO at CKD and Bio Business Team of New Business Division in Samsung Electronics and held the position of Vice President . Prior to that, he served as Head of Product Development Division in LG Life Sciences Ltd. Dr Kim received his B.S in Biochemistry from Yonsei University, MBA degree from Sogang University and Ph.D. in Chemistry from University of Northern Illinois and postdoctoral training at University of Florida, Gainesville.
  • You Suk Suh, Ph.D.
    CEO, R&D
    You Suk Suh has served as CEO and Head of R&D since August 2015. Dr. Suh joined Genexine in 2006 and held multiple leadership positions over the years in Genexine, including Head of Bio Efficacy Center before taking his current position. Dr. Suh received his Ph.D. degree from POSTECH (Korea) and postdoctoral training at Deutches Primatenzentrum GmbH (Germany). He worked as research follow at Alexander-von-Humboldt foundation prior to joining Genexine.
  • Jong Sup Park, M.D., Ph.D.
    Gynecologic Oncologist
    Executive Vice President, Chief Medical Officer
    Jong Sup Park joined Genexine as Executive Vice President and Chief Medical Officer since March 2019 after retirement in Catholic Medical Center. Dr. Park had served as a Director in Gynecological Cancer Center of Seoul St. Mary’s Hospital, Catholic University of Korea and remains as Professor Emeritus. Also, he was former research professor at Johns Hopkins medical school, department of microbiology. He had dedicated himself as a representative Gynecologic Oncologist in Korea as well as a well-known Biomedical Researcher on HPV and Cervical Cancer for 30 years. In addition, he established AOGIN (Asia-Oceania Research Organization on Genital Infection and Neoplasia) to educate clinicians and health workers who were living in Asia-Pacific region.
  • Hyi-Jeong Ji, Ph.D.
    Executive Vice President, Head of Bio Research Institute, QA
    Hyi-Jeong Ji is Executive Vice President and Head of Bio Research Institute and joined Genexine in January 2018. Prior to joining Genexine, Dr. Ji held Senior Vice President position of Corporate Development at GreenGross Corp. Prior to that, she served as Vice President of Product Development Division in LG Life Sciences Ltd leading hGH Development project. Dr. Ji received B.S and M.S in Biochemistry from Yonsei University, Ph.D. in Biochemistry from Purdue University, and MBA degree from LG MBA.
  • Kwang Ho Kim
    Executive Vice President, Chief Operating Officer
    KwangHo Kim joined Genexine as Chief Operating Officer in 2018 from Johnson and Johnson, where he led its North Asia Consumer business as Area Managing Director. Prior to JnJ, Mr. Kim worked at Mars Inc. for sixteen years in various executive roles including Head of North Asia and General Manager Korea. Mr. Kim started his career at Samsung where he worked in a number of engineering projects for ten years. Mr. Kim received his B.A. in Mechanical Engineering from Pusan National University.
  • Young-Joon Lee, MD, PhD, MBA
    Executive Vice President, Chief Strategy Officer(CSO)
    Young-Joon Lee joined Genexine in April 2019 as Chief Strategy Officer and he is in charge of Strategy Planning Division. Dr. Lee has more than 27 years of experiencing medical practice, biomedical research and health information technology industry.
    Prior to joining Genexine, he was a CEO of AIMMED Co. and a leading business expert in providing comprehensive digital health services as well as developing biomedical products during the past 16 years. In 2011, he had founded AmKoHealthcare Inc., a U.S.-based health ICT company headquartered in Texas, and successfully performed collaborative projects developing digital healthcare solutions in cooperation with LG CNS Co. and long-term care companies in the U.S. He also worked with MEDIPOST Co. as an Associate Research Director to develop cell-based cancer immunotherapeutics.
    He worked for National Cancer Center Hospital in Korea as a Senior Director in the Department of Laboratory Medicine from 2000 to 2003 and had research career in genetic diagnostics and cancer immunotherapy. He graduated and received M.D. from Seoul National University College of Medicine. He earned his Master and Ph.D. in Medical Science degree from the Seoul National University Graduate School and then completed M.B.A. degree from the Ajou University Graduate School of Business.
  • Jung Won Woo, Ph.D.
    Senior Vice President, Head of Clinical Division
    Jung won Woo is in charge of Clinical Planning and joined Genexine in 2013. Previously, Dr. Woo was Senior Researcher at Samsung Bio Research Institute and later at Convergent Research Consortium for Immunologic Disease in Seoul St Mary’s Hospital. Dr. Woo received her B.S. and M.S. in Pharmacy from Seoul National University and Ph.D. in Microbiology from Cornell University. She did her postdoctoral fellowship at Harvard Medical School.
  • Yong Min Won, MBA
    Senior Vice President, CFO
    Yong Min Won joined Genexine in April 2017 as Chief Financial Officer, and he is in charge of Finance and IR/PR. Prior to joining Genexine, Mr. Won served as Executive Director at Handok Inc. for five years. Prior to that, he was Head of International Business in Hana Daetoo Securities and have more than 17 years’ experience in financial industry. Mr. Won received his B.A in Business Administration from Korea University and MBA degree from Cornell University.

Board of Directors

Young Chul Sung, Ph.D.
Founder & Chief Technology Officer,Genexine
and Chairman of the Board of Directors
You Suk Suh, Ph.D.
CEO, Head of DNAResearch Institute
Hyi-Jeong Ji, Ph.D.
Executive Vice President, Head of Bio
Research Institute
Young-Jin Kim
Chairman & CEO, Handok
Mi-Chung Ahn, Ph.D.
Managing Partner, Eruum Patent Law Firm
Sung Ki Baik, Ph.D.
Director, Korea-Asean Friendship Association
Tae Yong Lee
CEO, Intervest


Introduction of Genexine CI

Logo Framework

The Genexine logo consists of the brand name.

Minimum Size

The Genexine logo must appear in the specified proportions. The Genexine logo should not be reproduced smaller than the minimum recommended size of 0.5” H x 1.5” W for printing materials.

Corporate Colors

Consistent use of color across all media is essential to the integrity of the Genexine identity. Below are the approved color variations for print (CMYK) and web (RGB) formats. Note that no other color specifications should be utilized. The Genexine logo may be used on any medium with a white background.

Full Color | White Background
  • Print: CMYK

    C=100 M=25 Y=0 K=50

    Web/Screen (includes powerpoint): RGB

    R=0 G=85 B=129

  • Print: CMYK

    C=0 M=100 Y=79 K=20

    Web/Screen (includes powerpoint): RGB

    R=196 G=18 B=48

Acceptable Logo

The following examples demonstrate a broad range of background applications.

  • Grayscale | White Background
  • Black | White Background
  • White | Black Background

Incorrect Use

The functional and aesthetic aspect of the logo has been established. Altering the Genexine colors or proportions fractionalize the brand identity and reduce brand recognition.

  • Logo too small
  • Do not use the logo
    on a dark background
  • Do not intrude on
    the visual space of the logo
  • Insufficient background contrast